Full Press Release Details
Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology.
ALLO
Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Key Takeaway: Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology